首页|Massachusetts Institute of Technology Reports Findings in Artificial Intelligenc e (Interpretable artificial intelligence to optimise use of imatinib after resec tion in patients with localised gastrointestinal stromal tumours: an observation al …)
Massachusetts Institute of Technology Reports Findings in Artificial Intelligenc e (Interpretable artificial intelligence to optimise use of imatinib after resec tion in patients with localised gastrointestinal stromal tumours: an observation al …)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning DailyNews Daily News – New research on Artificial Intelligenc e is the subject of a report. According to newsreporting out of Cambridge, Mass achusetts, by NewsRx editors, research stated, “Current guidelinesrecommend use of adjuvant imatinib therapy for many patients with gastrointestinal stromal tu mours(GISTs); however, its optimal treatment duration is unknown and some patie nt groups do not benefitfrom the therapy. We aimed to apply state-of-the-art, i nterpretable artificial intelligence (ie, predictionsor prescription logic that can be easily understood) methods on real-world data to establish which groupsof patients with GISTs should receive adjuvant imatinib, its optimal treatment d uration, and the benefitsconferred by this therapy.”
CambridgeMassachusettsUnited StatesNorth and CentralAmericaAntineoplasticsArtificial IntelligenceBCR-ABL Ty rosine Kinase InhibitorsClinical ResearchClinical Trials and StudiesDrugs and TherapiesEmerging TechnologiesGastroenterologyHealth and MedicineIma tinib TherapyMachine LearningPharmaceuticalsProtein Kinase InhibitorsTyr osine Kinase Inhibitors
NETL
NSTL
